ECSP099471A - Formas cristalinas de glyt1 - Google Patents
Formas cristalinas de glyt1Info
- Publication number
- ECSP099471A ECSP099471A EC2009009471A ECSP099471A ECSP099471A EC SP099471 A ECSP099471 A EC SP099471A EC 2009009471 A EC2009009471 A EC 2009009471A EC SP099471 A ECSP099471 A EC SP099471A EC SP099471 A ECSP099471 A EC SP099471A
- Authority
- EC
- Ecuador
- Prior art keywords
- manufacture
- glyt1
- present
- glass forms
- trifluor
- Prior art date
Links
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 239000011521 glass Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP099471A true ECSP099471A (es) | 2009-07-31 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2009009471A ECSP099471A (es) | 2006-12-28 | 2009-06-26 | Formas cristalinas de glyt1 |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (OSRAM) |
| EP (1) | EP2114405B1 (OSRAM) |
| JP (1) | JP4799666B2 (OSRAM) |
| KR (1) | KR101130146B1 (OSRAM) |
| CN (1) | CN101573114A (OSRAM) |
| AR (1) | AR064545A1 (OSRAM) |
| AU (1) | AU2007341356B2 (OSRAM) |
| BR (1) | BRPI0720829B8 (OSRAM) |
| CA (1) | CA2673667A1 (OSRAM) |
| CL (1) | CL2007003830A1 (OSRAM) |
| CO (1) | CO6190613A2 (OSRAM) |
| CR (1) | CR10846A (OSRAM) |
| CY (1) | CY1116350T1 (OSRAM) |
| DK (1) | DK2114405T3 (OSRAM) |
| EC (1) | ECSP099471A (OSRAM) |
| ES (1) | ES2535040T3 (OSRAM) |
| HR (1) | HRP20150573T1 (OSRAM) |
| HU (1) | HUE025032T2 (OSRAM) |
| MA (1) | MA31029B1 (OSRAM) |
| MX (1) | MX2009006859A (OSRAM) |
| MY (1) | MY188367A (OSRAM) |
| NO (1) | NO342150B1 (OSRAM) |
| NZ (1) | NZ577502A (OSRAM) |
| PE (1) | PE20081556A1 (OSRAM) |
| PL (1) | PL2114405T3 (OSRAM) |
| PT (1) | PT2114405E (OSRAM) |
| RS (1) | RS53910B1 (OSRAM) |
| RU (1) | RU2463295C2 (OSRAM) |
| SI (1) | SI2114405T1 (OSRAM) |
| TW (1) | TWI388552B (OSRAM) |
| UA (1) | UA100232C2 (OSRAM) |
| WO (1) | WO2008080821A1 (OSRAM) |
| ZA (1) | ZA200904423B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ577502A (en) | 2006-12-28 | 2012-02-24 | Hoffmann La Roche | Crystalline forms glyt1 |
| JP6074142B2 (ja) | 2009-02-26 | 2017-02-01 | タール ファーマシューティカルズ，インコーポレイテッド | 医薬化合物の結晶化 |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| BR112014028872A2 (pt) * | 2012-05-25 | 2017-06-27 | Basf Se | forma b cristalina, processo para a produção das formas b e ab, mistura da forma b cristalina, agente de proteção, uso da forma b cristalina e método para o combate do crescimento indesejado dos vegetais |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| EP4087570A4 (en) | 2020-01-09 | 2024-04-03 | Disc Medicine, Inc. | METHODS OF TREATING ERYTHROPOIETIC PROTOPORPHYRIA, X-LINKED PROTOPORPHYRIA OR CONGENITAL ERYTHROPOIETIC PORPHYRIA WITH GLYCINE TRANSPORT INHIBITORS |
| JP7096958B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| EP4337199A4 (en) * | 2021-05-14 | 2025-03-19 | Disc Medicine, Inc. | Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents |
| US20240390362A1 (en) * | 2021-05-27 | 2024-11-28 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| UA85194C2 (ru) * | 2003-08-11 | 2009-01-12 | Ф.Хоффманн-Ля Рош Аг | Пиперазины с or-замещенной фенильной группой и их применение как ингибиторов glyt 1 |
| NZ577502A (en) | 2006-12-28 | 2012-02-24 | Hoffmann La Roche | Crystalline forms glyt1 |
-
2007
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0720829B8 (pt) | formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende | |
| ECSP066358A (es) | PIPERAZINA CON GRUPO FENIL OR-SUSTITUIDO Y SU USO COMO INHIBIDORES GlyT1 | |
| DOP2009000258A (es) | Compuestos amino-heterociclicos | |
| BRPI0414209B8 (pt) | derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento | |
| CU20110106A7 (es) | Nuevos compuestos 578 | |
| UY30408A1 (es) | Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| CO6362014A2 (es) | Compuestos con anillos espiro - triciclicos como moduladores de beta-secretasaa y metodos de uso | |
| UY32391A (es) | Compuestos amino-heterocíclicos | |
| DOP2017000030A (es) | COMPUESTOS DERIVADOS DE ESPIRO 1,2-IMIDAZOL Y SU USO COMO INHIBIDORES DE beta-SECRETASA (BACE) | |
| BRPI0414541A8 (pt) | compostos heterocíclicos fundidos, seu uso, método de preparação de compostos intermediários e método para estudar distúrbios mediados por serotonina | |
| ECSP10010506A (es) | Derivados de 1-heterociclilo-1,5-dihidro-pirazol [3,4-D] pirimidino-4-ona y su uso como inhibidores de PDE9A. | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
| PH12012501122A1 (en) | Pteridinones as inhibitors of polo-like kinase | |
| EA201291413A1 (ru) | Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции | |
| ECSP11010947A (es) | Compuestos n- sulfonamido pirazolil policíclicos | |
| EA201592278A1 (ru) | Производные 4-амино-6-фенил-5,6-дигидроимидазо[1,5-a]пиразин-3(2h)-она в качестве ингибиторов бета-секретазы (bace) | |
| EA201592277A1 (ru) | Производные 4-амино-6-фенил-5,6-дигидроимидазо[1,5-a]пиразина в качестве ингибиторов бета-секретазы | |
| UY29451A1 (es) | Derivados novedosos de (1,3)tiazolo(4,5-d)pirimidin-2-(3h)-ona 5,7-disustituida | |
| NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
| UY30612A1 (es) | Derivados 5,7 disustituidos de la [1,3]tiazolo[4,5,d]pirimidin-2(3h)-ona, proceso de preparacion y aplicaciones | |
| ATE496534T1 (de) | Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden | |
| TH92210B (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) | |
| TH107358A (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) |